Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study.
Liu J, Li J, Lin W, Shao D, Depypere L, Zhang Z, Li Z, Cui F, Du Z, Zeng Y, Jiang S, He P, Gu X, Chen H, Zhang H, Lin X, Huang H, Lv W, Cai W, Liang W, Liang H, Jiang W, Wang W, Xu K, Cai W, Wu K, Lerut T, Fu J, He J.
Liu J, et al.
Int J Cancer. 2022 Jul 1;151(1):128-137. doi: 10.1002/ijc.33976. Epub 2022 Mar 21.
Int J Cancer. 2022.
PMID: 35188268
Clinical Trial.